Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2022
Historique:
pubmed: 24 5 2022
medline: 14 7 2022
entrez: 23 5 2022
Statut: ppublish

Résumé

Coding variation in the Leucine rich repeat kinase 2 gene linked to Parkinson's disease (PD) promotes enhanced activity of the encoded LRRK2 kinase, particularly with respect to autophosphorylation at S1292 and/or phosphorylation of the heterologous substrate RAB10. To determine the inter-laboratory reliability of measurements of cellular LRRK2 kinase activity in the context of wildtype or mutant LRRK2 expression using published protocols. Benchmark western blot assessments of phospho-LRRK2 and phospho-RAB10 were performed in parallel with in situ immunological approaches in HEK293T, mouse embryonic fibroblasts, and lymphoblastoid cell lines. Rat brain tissue, with or without adenovirus-mediated LRRK2 expression, and human brain tissues from subjects with or without PD, were also evaluated for LRRK2 kinase activity markers. Western blots were able to detect extracted LRRK2 activity in cells and tissue with pS1292-LRRK2 or pT73-RAB10 antibodies. However, while LRRK2 kinase signal could be detected at the cellular level with over-expressed mutant LRRK2 in cell lines, we were unable to demonstrate specific detection of endogenous cellular LRRK2 activity in cell culture models or tissues that we evaluated. Further development of reliable methods that can be deployed in multiple laboratories to measure endogenous LRRK2 activities are likely required, especially at cellular resolution.

Sections du résumé

BACKGROUND
Coding variation in the Leucine rich repeat kinase 2 gene linked to Parkinson's disease (PD) promotes enhanced activity of the encoded LRRK2 kinase, particularly with respect to autophosphorylation at S1292 and/or phosphorylation of the heterologous substrate RAB10.
OBJECTIVE
To determine the inter-laboratory reliability of measurements of cellular LRRK2 kinase activity in the context of wildtype or mutant LRRK2 expression using published protocols.
METHODS
Benchmark western blot assessments of phospho-LRRK2 and phospho-RAB10 were performed in parallel with in situ immunological approaches in HEK293T, mouse embryonic fibroblasts, and lymphoblastoid cell lines. Rat brain tissue, with or without adenovirus-mediated LRRK2 expression, and human brain tissues from subjects with or without PD, were also evaluated for LRRK2 kinase activity markers.
RESULTS
Western blots were able to detect extracted LRRK2 activity in cells and tissue with pS1292-LRRK2 or pT73-RAB10 antibodies. However, while LRRK2 kinase signal could be detected at the cellular level with over-expressed mutant LRRK2 in cell lines, we were unable to demonstrate specific detection of endogenous cellular LRRK2 activity in cell culture models or tissues that we evaluated.
CONCLUSION
Further development of reliable methods that can be deployed in multiple laboratories to measure endogenous LRRK2 activities are likely required, especially at cellular resolution.

Identifiants

pubmed: 35599495
pii: JPD213128
doi: 10.3233/JPD-213128
pmc: PMC9398093
doi:

Substances chimiques

LRRK2 protein, human EC 2.7.11.1
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 EC 2.7.11.1
rab GTP-Binding Proteins EC 3.6.5.2
Leucine GMW67QNF9C

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1423-1447

Subventions

Organisme : NINDS NIH HHS
ID : P50 NS108675
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS064934
Pays : United States

Références

Mov Disord. 2015 Feb;30(2):180-9
pubmed: 25448543
J Neurosci. 2016 Jul 13;36(28):7415-27
pubmed: 27413152
Acta Neuropathol Commun. 2017 Nov 22;5(1):86
pubmed: 29166931
J Biol Chem. 2015 Aug 7;290(32):19433-44
pubmed: 26078453
J Biol Chem. 2010 Sep 17;285(38):29569-76
pubmed: 20595391
Elife. 2017 Nov 10;6:
pubmed: 29125462
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Oxid Med Cell Longev. 2021 Jul 08;2021:9969842
pubmed: 34306319
Sci Transl Med. 2012 Dec 12;4(164):164ra161
pubmed: 23241745
J Cell Biol. 2022 Apr 4;221(4):
pubmed: 35266954
Hum Mol Genet. 2012 Feb 15;21(4):890-9
pubmed: 22080837
Bio Protoc. 2021 Sep 05;11(17):e4140
pubmed: 34604446
Ann Neurol. 2005 Jun;57(6):918-21
pubmed: 15880653
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Biochem J. 2018 Jan 2;475(1):23-44
pubmed: 29127255
Lancet. 2005 Jan 29-Feb 4;365(9457):415-6
pubmed: 15680457
Cell. 2021 Jun 24;184(13):3519-3527.e10
pubmed: 34107286
Nat Neurosci. 2006 Oct;9(10):1231-3
pubmed: 16980962
Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):17296-17307
pubmed: 32631998
Neuron. 2004 Nov 18;44(4):595-600
pubmed: 15541308
Lancet Neurol. 2019 Dec;18(12):1091-1102
pubmed: 31701892
Mov Disord. 2017 Oct;32(10):1432-1438
pubmed: 28639421
Hum Mol Genet. 2011 Oct 15;20(R2):R158-62
pubmed: 21875901
Elife. 2016 Jan 29;5:
pubmed: 26824392
EMBO J. 2018 Jan 4;37(1):1-18
pubmed: 29212815
Hum Mol Genet. 2019 Nov 1;28(21):3552-3568
pubmed: 31428781
Cell. 2020 Sep 17;182(6):1508-1518.e16
pubmed: 32783917
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Neuron. 2004 Nov 18;44(4):601-7
pubmed: 15541309
J Comp Neurol. 2014 Aug 1;522(11):2465-80
pubmed: 24633735
NPJ Parkinsons Dis. 2018 Apr 19;4:13
pubmed: 29707617
Biochem J. 2021 Jan 29;478(2):299-326
pubmed: 33367571
Front Mol Neurosci. 2017 Dec 14;10:417
pubmed: 29311810
Biochem J. 2018 Jun 6;475(11):1861-1883
pubmed: 29743203
Nat Rev Neurosci. 2010 Dec;11(12):791-7
pubmed: 21088684
JAMA Neurol. 2018 Nov 1;75(11):1416-1422
pubmed: 30039155
Biochem J. 2010 Sep 15;430(3):393-404
pubmed: 20642453
Ann Neurol. 2002 Mar;51(3):296-301
pubmed: 11891824
Neurobiol Dis. 2012 Sep;47(3):385-92
pubmed: 22668778
Biochem J. 2013 Jul 1;453(1):101-13
pubmed: 23560750
FASEB J. 2020 Nov;34(11):14217-14233
pubmed: 32926469
Biochem J. 2020 Nov 27;477(22):4397-4423
pubmed: 33135724
Nat Commun. 2014 Dec 15;5:5827
pubmed: 25500533
Nature. 2020 Dec;588(7837):344-349
pubmed: 32814344
Cells. 2020 Oct 22;9(11):
pubmed: 33105882
J Neurosci. 2011 Jan 19;31(3):907-12
pubmed: 21248115
Hum Mol Genet. 2017 Jul 15;26(14):2747-2767
pubmed: 28453723
Biochem J. 2019 Oct 15;476(19):2797-2813
pubmed: 31527116
Sci Transl Med. 2020 Apr 22;12(540):
pubmed: 32321864
Hum Mol Genet. 2018 Jan 15;27(2):385-395
pubmed: 29177506
PLoS One. 2012;7(6):e39132
pubmed: 22723946
Sci Transl Med. 2018 Jul 25;10(451):
pubmed: 30045977
Elife. 2018 Nov 06;7:
pubmed: 30398148
EMBO Rep. 2015 Jan;16(1):79-86
pubmed: 25427558
Mol Neurodegener. 2021 Mar 19;16(1):17
pubmed: 33741046
Protein Sci. 2022 Jan;31(1):129-140
pubmed: 34601771

Auteurs

Belén Fernández (B)

Institute of Parasitology and Biomedicine López-Neyra (IPBLN), Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain.

Vinita G Chittoor-Vinod (VG)

Department of Pathology, Stanford University, Stanford, CA, USA.

Jillian H Kluss (JH)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

Kaela Kelly (K)

Duke Center for Neurodegeneration Research, Department of Pharmacology, Duke University, Durham, NC, USA.

Nicole Bryant (N)

Duke Center for Neurodegeneration Research, Department of Pharmacology, Duke University, Durham, NC, USA.

An Phu Tran Nguyen (APT)

Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Syed A Bukhari (SA)

Department of Pathology, Stanford University, Stanford, CA, USA.

Nathan Smith (N)

Department of Biochemistry, Redox Biology Center, The University of Nebraska-Lincoln, NE, USA.

Antonio Jesús Lara Ordóñez (AJ)

Institute of Parasitology and Biomedicine López-Neyra (IPBLN), Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain.

Elena Fdez (E)

Institute of Parasitology and Biomedicine López-Neyra (IPBLN), Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain.

Marie-Christine Chartier-Harlin (MC)

Univ. Lille, INSERM, CHU Lille, UMR-S, LilNCog - Centre de Recherche Lille Neurosciences & Cognition, Lille, France.

Thomas J Montine (TJ)

Department of Pathology, Stanford University, Stanford, CA, USA.

Mark A Wilson (MA)

Department of Biochemistry, Redox Biology Center, The University of Nebraska-Lincoln, NE, USA.

Darren J Moore (DJ)

Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Andrew B West (AB)

Duke Center for Neurodegeneration Research, Department of Pharmacology, Duke University, Durham, NC, USA.

Mark R Cookson (MR)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

R Jeremy Nichols (RJ)

Department of Pathology, Stanford University, Stanford, CA, USA.

Sabine Hilfiker (S)

Department of Anesthesiology and Department of Pharmacology, Physiology and Neuroscience, Rutgers New Jersey Medical School, Newark, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH